Background: Previous clinical studies have reported that extracorporeal shock wave (EPSW) monotherapy can effectively treat avascular necrosis of femoral head (ANFH). However, no systematic review has been conducted to assess its effectiveness and safety for patients with ANFH. Therefore, this study will systematically assess the effectiveness and safety of EPSW monotherapy for patients with ANFH.
Introduction
Avascular necrosis of femoral head (ANFH) is a very common progressive orthopedic disorder. [1] [2] [3] This condition often manifests as severe pain, limitation of lower limbs activity. [4] [5] [6] It mainly affects patients those aged between 20 to 50 years old. [7] Many factors are responsible for this disorder, such as diabetes, hypertension, vasculitis, pancreatitis, and so on. [8] [9] [10] [11] [12] [13] Thus, effective managements for this disorder are very important and necessary. Otherwise, it may lead to poor quality of life in patients who suffer from this disorder. [14] [15] [16] Extracorporeal shock wave (EPSW) has been reported to treat a variety of orthopedic disorders effectively, such as chronic rotator cuff tendonitis, rheumatoid arthritis, chronic plantar fasciitis, and ANFH, especially for ANFH. [17] [18] [19] Lots of clinical trials have reported that EPSW has been used for ANFH treatment, and has achieved a promising effectiveness. [20] [21] [22] [23] [24] [25] [26] [27] [28] However, up to present, no study systematically has investigated the effectiveness and safety of EPSW for ANFH. Therefore, this systematic review will assess the effectiveness and safety of EPSW for patients with ANFH.
Methods and analysis
2.1. Study selection criteria 2.1.1. Types of studies. Only randomized controlled trials (RCTs) evaluating the effectiveness and safety of EPSW for ANFH will be considered for inclusion in this study. The other studies, such as non-RCTs, non-controlled trials, non-clinical studies, and quasi-RCTs will be excluded in this study.
Types of participants.
Patients with clinically diagnosed with ANFH will be fully considered for inclusion with any restrictions, such as race, age, and gender.
Types of treatments.
In the experimental group, only EPSW monotherapy will be considered for inclusion. In the control group, any kinds of interventions can be used, except any forms of EPSW alone or combination.
2.1.4. Types of outcome measurements. The primary outcome is pain intensity. It can be measured by any pain instruments, such as visual analog scale.
The secondary outcomes are functional status of attacked femoral head, as measured by any relevant scales, such as Western Ontario and McMaster Universities Osteoarthritis Index; quality of life, as evaluated by any associated measurement tools, such as The 36-Item Short Form Health Survey; and any adverse events.
Search strategy
Cochrane Library, EMBASE, PUBMED, Cumulative Index to Nursing and Allied Health Literature, China National Knowledge Infrastructure, and Chinese Biomedical Literature Database will be searched from their inceptions to the present without any language restrictions. Reference lists of relevant studies will also be searched to avoid missing any potential eligible RCTs. The search strategy for Cochrane Library has been developed in consultation with an experienced librarian and is shown in Table 1 . This search strategy will also be adapted and applied to other databases.
Study selection
Two authors will independently scanning the title, or/and abstract initially. Full texts will be further read if insufficient information can be utilized for judgment by screening title and abstract only. All disagreements regarding study selection have arisen between 2 authors, and a third experienced author will help to solve them by discussion. This study has been reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [29] and PRISMA-Protocol guidelines. [30, 31] Additionally, a PRISMA flow chart will be utilized to provide transparency of number of studies with specific inclusion and exclusion at each stage.
Data extraction and management
Two authors will independently extract data according to the pre-designed data extraction sheet. The sheet includes the following information: title, first author, year of publication, country, funding information, setting, study design and methods (such as randomization, blinding, and concealment), sample size, dosage, treatment frequency, and duration, and all primary, secondary and other outcome measurements. If any divergences regarding the data extraction between 2 authors exist, a third experienced author will be consulted and settle them down through discussion.
Risk of bias assessment
Risk of bias assessment will be assessed by using Cochrane Handbook of Systematic Review of Interventions. It comprises of 7 fields, and each field is categorized as a high risk of bias, unclear risk of bias, or low risk of bias. Two authors will independently conduct the risk of bias assessment. A third experienced author will act as an arbiter through discussion if any disagreements arise between 2 authors.
2.6. Statistical analysis 2.6.1. Treatment effect measurement. The risk ratio and 95% confidence intervals (CIs) will be presented for dichotomous data, while the mean difference, or standardized mean difference and 95% CIs will be expressed for continuous data.
Heterogeneity evaluation. The test of I
2 will be utilized to check the heterogeneity among included studies. There is reasonable heterogeneity among those included studies if I 2 50%. On the other hand, there is substantial heterogeneity among those include studies if I 2 >50%.
Data synthesis.
If acceptable heterogeneity will be detected, a fixed-effect model will be used to pool the data, and meta-analysis will be conducted. On the other hand, if substantial heterogeneity will be identified, a random-effect model will be used to pool the data. Meanwhile, subgroup analysis will be performed to detect any reasons that may cause significant heterogeneity. If there is acceptable heterogeneity after the subgroup analysis, meta-analysis will be conducted. Otherwise, there is still substantial heterogeneity after the subgroup analysis, meta-analysis will not be conducted, and a narrative description will be elaborated instead.
Subgroup analysis.
If heterogeneity is substantial among those included studies, subgroup analysis will be performed in accordance with different characteristics, treatments, controls, and outcome instruments.
2.6.5. Sensitivity analysis. Sensitivity analysis will be carried out to check the robustness of pooled results by removing low quality of studies.
2.6.6. Reporting bias. Funnel plot and Egger test will be conducted to check any possible of the reporting bias if more than 10 eligible RCTs are included in this study.
Discussion
This systematic review is the first study to investigate the effectiveness and safety of EPSW monotherapy for patients with ANFH. Its findings will supply a detailed summary of the up-todate evidence relevant of EPSW in pain relief, improvement of functional status of attacked femoral head, and enhancement of quality of life in patients with ANFH. This evidence may be helpful to clinician, patients, as well as the health policy makers regarding the use of EPSW for the treatment of ANFH. 
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